Dianthus Therapeutics, Inc. /DE/
DNTHNext catalyst
Claseprubart
Multifocal Motor Neuropathy
Get an email about DNTH's next catalysts
Track Dianthus Therapeutics, Inc. /DE/ (DNTH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
Claseprubart Phase 2 Est. Readout (MOMENTUM)
Estimated primary completion for Claseprubart trial (NCT06537999) in Multifocal Motor Neuropathy. Topline data typically follows completion by weeks to months.
SourceDNTH Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $1.00 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DNTH103 | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Claseprubart | Phase 3 | Multifocal Motor Neuropathy | - | - |
Frequently asked questions
What is in Dianthus Therapeutics, Inc. /DE/'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Dianthus Therapeutics, Inc. /DE/'s (DNTH) pipeline across Phase 3. Its lead program is Claseprubart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dianthus Therapeutics, Inc. /DE/'s next FDA catalyst?→
Dianthus Therapeutics, Inc. /DE/'s (DNTH) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DNTH biotech catalysts?→
Add DNTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dianthus Therapeutics, Inc. /DE/'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.